Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia Pipeline Review, H2 2017, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape. Hyperalgesia is an increase in pain response. Predisposing factors include long term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves and psychological disorders. Treatment includes antidepressants and Non-steroidal anti-inflammatory drugs.
Hyperalgesia Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Single User License PDF Report of 31 pages at: http://www.reportsnreports.com/purchase.aspx?name=1125818
The Hyperalgesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Discount is available on Diarrhea report at http://www.reportsnreports.com/contacts/discount.aspx?name=1125818
Hyperalgesia – Companies Involved in Therapeutics Development – Cara Therapeutics Inc and Novartis AG
List of Tables
Number of Products under Development for Hyperalgesia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hyperalgesia – Pipeline by Boehringer Ingelheim GmbH, H2 2017
Hyperalgesia – Pipeline by Cara Therapeutics Inc, H2 2017
Hyperalgesia – Pipeline by Novartis AG, H2 2017
Hyperalgesia – Dormant Projects, H2 2017
ReportsandReports.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441